The big C: China biotech start-ups get cutting edge on cancer
The evolution of cancer treatments in China is a bellwether for biotech development in the country and its capacity for genuine innovation. Most PE and VC investors aren’t shying away
“The core reason for the formation of tumors is the aging of the human body. As people live longer, the chances of getting tumors are greater. In addition, there is no method to completely cure tumors....
More on Greater China
Latest News
Carlyle faces activist challenge to Japan Asia Group deal
An investment firm with ties to renowned Japanese activist investor Yoshiaki Murakami is challenging The Carlyle Group’s JPY37 ($355 million) bid for Japan Asia Group by launching a tender offer of its own.
Hong Kong regulation: Carry on
The proposal to place a 0% tax on carried interest has been welcomed in Hong Kong, but PE industry participants are quietly looking to Hong Kong Monetary Authority to ensure balanced execution of the policy
Fund focus: Oceanpine opens to external capital
Technology and healthcare-focused Oceanpine Capital sees the large GP commitment to its fund and the network of its founder as key differentiators in a competitive Chinese market
CPE, SDIC lead $46m round for China's Jaka Robotics
Chinese industrial robot manufacturer Jaka Robotics has raised RMB300m ($46m) in Series C funding led by CPE and State Development and Investment Corporation (SDIC).